Susan E. Graf's most recent trade in Cg Oncology Inc. was a trade of 9,354 Director Stock Option (right to buy) done . Disclosure was reported to the exchange on June 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cg Oncology Inc | Susan E. Graf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2026 | 9,354 | 9,354 | - | - | Director Stock Option (right to buy) | |
| Aardvark Therapeutics Inc | Susan E. Graf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 30,508 | 30,508 | - | - | Stock Option (right to buy) | |
| Cg Oncology Inc | Susan E. Graf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 24,165 | 24,165 | - | - | Director Stock Option (right to buy) | |
| Cg Oncology Inc | Susan E. Graf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,600 | 15,600 | - | - | Stock Option (Right to Buy) | |
| Finch Therapeutics Group Inc | Susan E. Graf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 44,843 | 44,843 | - | - | Stock Option (right to buy) |